Edition:
United States

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

19.07USD
4:00pm EDT
Change (% chg)

$-0.18 (-0.94%)
Prev Close
$19.25
Open
$19.14
Day's High
$19.24
Day's Low
$18.86
Volume
331,856
Avg. Vol
526,281
52-wk High
$39.73
52-wk Low
$15.15

Latest Key Developments (Source: Significant Developments)

Myriad RBM announces agreement with Sanofi
Tuesday, 25 Oct 2016 07:05am EDT 

Myriad Genetics Inc : Announces an agreement with Sanofi to measure predictive cardiovascular biomarkers in patients with diabetes . Financial terms of deal were not disclosed .Under agreement, Sanofi will provide approximately 5,300 serum samples from elixa trial.  Full Article

Myriad Genetics to enter into a credit agreement
Thursday, 1 Sep 2016 04:25pm EDT 

Myriad Genetics Inc : Says on August 31 co entered into a credit agreement . Pursuant to credit agreement, Myriad borrowed term loans in an aggregate principal amount of $200.0 million .Proceeds of term loans used to finance acquisition of Assurex ,refinance certain existing indebtedness of Assurex and its units.  Full Article

Myriad Genetics reports Q4 earnings per share $0.32
Tuesday, 9 Aug 2016 04:05pm EDT 

Myriad Genetics : Reports fiscal fourth-quarter 2016 financial results . Q4 earnings per share $0.32 . Q4 earnings per share view $0.37 -- Thomson Reuters I/B/E/S . Q4 adjusted earnings per share $0.36 .Q4 revenue $186.5 million versus I/B/E/S view $187.9 million.  Full Article

Myriad Genetics board approves additional $200 mln share repurchase program
Tuesday, 7 Jun 2016 07:05am EDT 

Myriad Genetics Inc : Myriad board approves $200 million increase in share repurchase program .Approved an additional $200 million authorization for its share repurchase program.  Full Article

Myriad acquires Sividon Diagnostics for 35 mln euros
Tuesday, 31 May 2016 04:05pm EDT 

Myriad Genetics Inc : Myriad acquires Sividon Diagnostics . Has acquired Sividon Diagnostics for eur 35 million upfront with potential for eur 15 million in additional performance-based milestones .Myriad expects deal to be neutral to both revenue and earnings in fiscal year 2017.  Full Article

Myriad Genetics issues statement on HIPAA complaint
Thursday, 19 May 2016 04:56pm EDT 

Myriad Genetics Inc : Complaint filed against co with department of health and human services on behalf of four individuals seeking their genetic testing results . "company only provides personal information that correlates to person who requested it" . "we believe complaint lacks merit and should not be accepted" .Believes it complied with the requests and provided thefour patients with designated record set, all requested personal health information.  Full Article

Myriad Genetics expands strategic research collaboration with AbbVie
Tuesday, 23 Feb 2016 07:05am EST 

Myriad Genetics:Expands strategic research collaboration with AbbVie.Other terms of the deal were not disclosed.Under the terms of the agreement, AbbVie will use Myriad's CDx portfolio - myChoice HRD.  Full Article

Myriad Genetics Inc expands diagnostic research collaboration with TESARO and Merck
Monday, 22 Feb 2016 07:05am EST 

Myriad Genetics Inc:Expands diagnostic research collaboration with TESARO and Merck.Under the terms of the agreement, TESARO and Merck will use Myriad's myChoice HRD test.Other terms of deal were not disclosed.  Full Article

Myriad Genetics Inc gives Q3 2016 guidance below analysts' estimates; Maintains FY 2016 Revenue Guidance; Raises FY 2016 Earnings Guidance
Tuesday, 2 Feb 2016 04:05pm EST 

Myriad Genetics Inc:Company Maintains FY 2016 Revenue Guidance, Raises FY 2016 Earnings Guidance and Provides Q3 2016.Maintaining FY 2016 revenue guidance of $750 to $770 million and raising FY 2016 adjusted earnings per share guidance from the previous range of $1.60 to $1.65 to $1.63 to $1.68.Additionally, Myriad is issuing Q3 2016 financial guidance with revenues of $183 to $185 million and adjusted earnings per share of $0.37 to $0.39.Q3 2016 SHR VIEW $0.40, REV VIEW $190.1 MLN -- THOMSON REUTERS I/B/E/S.FY 2016 SHR VIEW $1.64, REV VIEW $759.3 MLN -- THOMSON REUTERS I/B/E/S.  Full Article

Myriad Genetics Inc gives Q2 2016 guidance; revenue guidance below analysts' estimates; reaffirms FY 2015 guidance
Tuesday, 3 Nov 2015 04:05pm EST 

Myriad Genetics Inc:Expects Q2 2016 total revenues of $188-$190 million and adjusted diluted earnings per share of $0.40-$0.42 (GAAP diluted EPS of $0.36-$0.38).Expects FY 2016 total revenues of $750-$770 million and adjusted diluted earnings per share of $1.60-$1.65 (GAAP diluted EPS of $1.45-$1.50).Q2 2016 revenue of $193 million and EPS of $0.42 - Thomson Reuters I/B/E/S.FY 2016 revenue of $758 million and EPS of $1.64 - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Myriad Genetics launches the endopredict test in U.S for patients with breast cancer

* Myriad Genetics launches the endopredict test in the United States for patients with breast cancer Source text for Eikon: Further company coverage: